/
IKT
$1.92-$0.01 (-0.78%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$252.2M
132M shares
52-week range
$1.33 – $2.26
63% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.92%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-14.95
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.0M | $1.1M | $698.5K | $3.1M | $123.4K | $260.5K | $0 | $0 |
| Cost of revenue | $3.6M | $2.6M | $893.8K | $11.4M | $6.7K | $13.6M | $26.3K | $0 |
| Gross profit | $393.8K | −$1.4M | −$195.3K | −$8.3M | $116.7K | −$13.4M | −$26.3K | $0 |
| Gross margin | 9.7% | -127.4% | -28.0% | -266.4% | 94.6% | -5127.8% | — | — |
| R&D | $3.6M | $2.6M | $893.8K | $11.4M | $12.0M | $13.6M | $17.2M | $29.8M |
| Operating income | −$2.1M | −$5.7M | −$2.8M | −$14.8M | −$18.1M | −$20.1M | −$28.6M | −$52.0M |
| EBITDA | $0 | $0 | $0 | $0 | −$18.0M | −$18.9M | −$27.5M | −$53.3M |
| Net income | −$2.2M | −$5.7M | −$2.8M | −$14.8M | −$18.1M | −$19.0M | −$27.5M | −$48.3M |
| Net margin | -53.3% | -509.7% | -407.7% | -476.9% | -14625.9% | -7304.8% | — | — |
| EPS (diluted) | -1.61 | -3.34 | -1.72 | -4.88 | -4.26 | -3.57 | -1.16 | -0.49 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $375000 | $-0.42 | $-0.47–$-0.38 | 4 |
| 2027 | $500000 | $-0.44 | $-0.52–$-0.40 | 3 |
| 2028 | $37M | $-0.40 | $-0.59–$-0.23 | 3 |
| 2029 | $165M | $-0.12 | $-0.12–$-0.12 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.41
Price
$1.92
Implied downside
-27%
Peer comparison
Inhibikase Therapeutics, Inc. Common Stock
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
www.inhibikase.com- Employees
- 35
- IPO / List date
- Dec 23, 2020
- HQ
- WILMINGTON, DE
Held by traders on TradeandTell
No one on the platform currently holds IKT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 16,500 | $27.7K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-06-30 | 1-for-6reverse |
Recent trades on TradeandTell
No one on the platform has traded IKT yet.
